Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Capital Expenditures (2021 - 2023)

Aligos Therapeutics' Capital Expenditures history spans 3 years, with the latest figure at $7000.0 for Q1 2023.

  • For Q1 2023, Capital Expenditures fell 98.64% year-over-year to $7000.0; the TTM value through Mar 2023 reached $435000.0, down 60.45%, while the annual FY2024 figure was $130000.0, 584.21% up from the prior year.
  • Capital Expenditures reached $7000.0 in Q1 2023 per ALGS's latest filing, down from $91000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $515000.0 in Q1 2022 to a low of $3000.0 in Q3 2022.
  • Average Capital Expenditures over 3 years is $204666.7, with a median of $152000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: surged 119.74% in 2022, then tumbled 98.64% in 2023.
  • A 3-year view of Capital Expenditures shows it stood at $336000.0 in 2021, then tumbled by 72.92% to $91000.0 in 2022, then crashed by 92.31% to $7000.0 in 2023.
  • Per Business Quant, the three most recent readings for ALGS's Capital Expenditures are $7000.0 (Q1 2023), $91000.0 (Q4 2022), and $3000.0 (Q3 2022).